Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1569 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 0.000427 | uM | 7827.068 | 0.9542 | 0.9219 | 1.1786 | |
| HCC1569 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 0.00213 | uM | 7827.068 | 0.8886 | 0.8092 | 1.1786 | |
| HCC1569 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 0.0107 | uM | 7827.068 | 0.7481 | 0.5635 | 1.1786 | |
| HCC1569 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 0.0533 | uM | 7827.068 | 0.6766 | 0.4357 | 1.1786 | |
| HCC1569 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 0.267 | uM | 7827.068 | 0.6570 | 0.4004 | 1.1786 | |
| HCC1569 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 1.33 | uM | 7827.068 | 0.6659 | 0.4165 | 1.1786 | |
| HCC1569 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 6.67 | uM | 7827.068 | 0.6664 | 0.4173 | 1.1786 | |
| HCC1569 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 33.3 | uM | 7827.068 | 0.5604 | 0.2235 | 1.1786 | |
| HCC1569 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 167 | uM | 7827.068 | 0.4296 | -0.0235 | 1.1786 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 0.0000853 | uM | 7450.069 | 1.0499 | 1.0438 | 2.2471 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 0.000427 | uM | 7450.069 | 1.0558 | 1.0489 | 2.2471 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 0.00213 | uM | 7450.069 | 1.0271 | 1.0239 | 2.2471 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 0.0107 | uM | 7450.069 | 0.9821 | 0.9840 | 2.2471 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 0.0533 | uM | 7450.069 | 1.0403 | 1.0355 | 2.2471 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 0.267 | uM | 7450.069 | 0.9298 | 0.9362 | 2.2471 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 1.33 | uM | 7450.069 | 0.8913 | 0.9002 | 2.2471 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 6.67 | uM | 7450.069 | 0.8579 | 0.8682 | 2.2471 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 33.3 | uM | 7450.069 | 0.8284 | 0.8392 | 2.2471 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 0.000427 | uM | 7830.068 | 0.9997 | 0.9997 | 1.8365 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 0.00213 | uM | 7830.068 | 0.9875 | 0.9864 | 1.8365 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 0.0107 | uM | 7830.068 | 1.0334 | 1.0361 | 1.8365 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 0.0533 | uM | 7830.068 | 0.7191 | 0.6713 | 1.8365 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 0.267 | uM | 7830.068 | 0.8953 | 0.8831 | 1.8365 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 1.33 | uM | 7830.068 | 0.7675 | 0.7317 | 1.8365 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 6.67 | uM | 7830.068 | 0.9721 | 0.9694 | 1.8365 |